Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors
Authors:
- 13 November 2013
- journal article
- Published by Springer Nature in Nature
- Vol. 504 (7480) , 437-440
Abstract
Glucose homeostasis is a vital and complex process, and its disruption can cause hyperglycaemia and type II diabetes mellitus. Glucokinase (GK), a key enzyme that regulates glucose homeostasis, converts glucose to glucose-6-phosphate in pancreatic β-cells, liver hepatocytes, specific hypothalamic neurons, and gut enterocytes. In hepatocytes, GK regulates glucose uptake and glycogen synthesis, suppresses glucose production, and is subject to the endogenous inhibitor GK regulatory protein (GKRP). During fasting, GKRP binds, inactivates and sequesters GK in the nucleus, which removes GK from the gluconeogenic process and prevents a futile cycle of glucose phosphorylation. Compounds that directly hyperactivate GK (GK activators) lower blood glucose levels and are being evaluated clinically as potential therapeutics for the treatment of type II diabetes mellitus. However, initial reports indicate that an increased risk of hypoglycaemia is associated with some GK activators. To mitigate the risk of hypoglycaemia, we sought to increase GK activity by blocking GKRP. Here we describe the identification of two potent small-molecule GK-GKRP disruptors (AMG-1694 and AMG-3969) that normalized blood glucose levels in several rodent models of diabetes. These compounds potently reversed the inhibitory effect of GKRP on GK activity and promoted GK translocation both in vitro (isolated hepatocytes) and in vivo (liver). A co-crystal structure of full-length human GKRP in complex with AMG-1694 revealed a previously unknown binding pocket in GKRP distinct from that of the phosphofructose-binding site. Furthermore, with AMG-1694 and AMG-3969 (but not GK activators), blood glucose lowering was restricted to diabetic and not normoglycaemic animals. These findings exploit a new cellular mechanism for lowering blood glucose levels with reduced potential for hypoglycaemic risk in patients with type II diabetes mellitus.Keywords
This publication has 28 references indexed in Scilit:
- Novel Pharmacological Approaches to the Treatment of Type 2 DiabetesPharmacological Reviews, 2012
- Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes MellitusJournal of Medicinal Chemistry, 2012
- Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy DogsMolecular Pharmacology, 2011
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Aqueous Process Chemistry: The Preparation of Aryl Sulfonyl ChloridesOrganic Process Research & Development, 2009
- Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory ProteinJournal of Biological Chemistry, 2008
- A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetesAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Defect in glucokinase translocation in Zucker diabetic fatty ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Characterization of Glucokinase Regulatory Protein-deficient MiceJournal of Biological Chemistry, 2000
- The mechanism by which rat liver glucokinase is inhibited by the regulatory proteinEuropean Journal of Biochemistry, 1990